Status:
COMPLETED
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
Lead Sponsor:
PATH
Collaborating Sponsors:
Naval Medical Research Center
Walter Reed Army Institute of Research (WRAIR)
Conditions:
Diarrhea
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin (dmLT) given by in...
Detailed Description
This is an open-label clinical trial in which a total of 50 participants will receive three injections of either CssBA alone, dmLT alone or CssBA + dmLT. The vaccine will be administered via IM inject...
Eligibility Criteria
Inclusion
- Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of enrollment.
- Completion and review of comprehension test (achieved \> 70% accuracy).
- Signed informed consent document.
- Available for the required follow-up period and scheduled clinic visits.
- Women: Negative pregnancy test with understanding (through informed consent process) to not become pregnant during the study or within three (3) months following last vaccination.
Exclusion
- Health problems (for example, intercurrent febrile illness, chronic medical conditions such as psychiatric conditions, diabetes mellitus, hypertension or any other condition that might place the subject at increased risk of adverse events) - study clinicians, in consultation with the PI, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the Research Monitor as appropriate.
- Clinically significant abnormalities on physical examination.
- Immunosuppressive drugs (use of systemic corticosteroids or chemotherapeutics that may influence antibody development) or illness (including immunoglobulin A \[IgA\] deficiency, defined by serum IgA \< 7 mg/dL).
- Women who are pregnant or planning to become pregnant during the study period plus three (3) months beyond the last received dose and currently nursing women.
- Participation in research involving another investigational product (defined as receipt of investigational product or exposure to invasive investigational device) 30 days before planned date of first vaccination or anytime through the last study safety visit.
- Positive blood test for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV), human immunodeficiency virus (HIV)-1/2.
- Clinically significant abnormalities on basic laboratory screening.
- Exclusionary skin disease history/findings that would confound assessment or prevent appropriate local monitoring of adverse events (AEs), or possibly increase the risk of a local AE
- History of chronic skin disease (clinician judgement)
- Acute skin infection/eruptions on the upper arms including fungal infections, severe acne or active contact dermatitis
- Allergies that may increase the risk of AEs
- Regular use (weekly or more often) of antidiarrheal, anti-constipation, or antacid therapy
- Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis; loose or liquid stools on other than an occasional basis
- History of microbiologically confirmed ETEC or cholera infection in the last 3 years
- Travel to countries where ETEC or V. cholerae or other enteric infections are endemic (most of the developing world) within 3 years prior to dosing (clinician judgement)
- Symptoms consistent with Travelers' Diarrhea or concurrent with travel to countries where ETEC infection is endemic (most of the developing world) within 3 years prior to dosing, OR planned travel to endemic countries during the length of the study
- Vaccination for or ingestion of ETEC, cholera, or E. coli heat labile toxin within 3 years prior to dosing
- Occupation involving handling of ETEC or V. cholerae currently, or in the past 3 years
Key Trial Info
Start Date :
January 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 26 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03404674
Start Date
January 16 2018
End Date
March 26 2019
Last Update
January 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Walter Reed Army Institute of Research Clinical Trial Center
Silver Spring, Maryland, United States, 20910